<DOC>
	<DOCNO>NCT02891005</DOCNO>
	<brief_summary>Study Purpose The safety efficacy paclitaxel control release balloon catheter VasoguardTM treatment small vessel lesion . Study Group Experimental group : paclitaxel control release balloon catheter ( VasoguardTM ) Control group : common balloon catheter ( Maverick2 )</brief_summary>
	<brief_title>Comparing Safety Efficacy Paclitaxel Controlled Release Balloon Catheter ( VasoguardTM ) Treatment Small Coronary Vessel Stenosis With Common Coronary Balloon Catheter ( Maverick2 )</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Subject need 18 80 year age male nonpregnant woman ; Subject stable anina pectoris , unstable anina pectoris , old myocardial infarction patient , ischemia evidence without symptom ; Subject life expectancy 2 year ; Lesion vessel reference diameter less equal 2.5mm , target lesion length less equal 40mm ; Target lesion stenosis equal great 70 % 50 % ischemia ; Single two coronary small vessel lesion situ ; Subject understand trail purpose , sign inform consent voluntarily , agree accept clinical telephone followup angiographic followup 9 month ; Target lesion preexpanded successfully ( Guide wire get lesion , balloon preexpand remnant stenosis vessel lumen less equal 50 % , without current limit interlayer thrombosis ) . Patient opinion investigator appropriate trail ; Pregnancy lactation female patient ; Patient life expectancy le 2 year ; Severe congestive heart failure NYHA IV heart failure ; Patient bleed constitution , use antithrombotic antiplatelet drug ; Patient happen acute myocardial infarction within week ; Patient happen stroke within six month ; Patient severe renal failure ( GFR≤30ml/Min ) ; Patient receive heart transplantation ; Patient tolerate aspirin / P2Y12 receptor inhibitor drug ; Patient allergy paclitaxel , PLGA contrast agent ; Peptic ulcer gastrointestinal bleeding within prior 6 month ; Patients participate another drug device clinical trail , complete primary endpoint follow period . Angiographic relevant： Merge three coronary small vessel lesion ; Target vessel extensive thrombosis evidence ; Restenosis vein graft bypass surgery ; Target lesion proximal exist seriously distort severe calcify lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>